Allspring Global Investments Holdings LLC boosted its position in Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) by 9,188.4% during the 3rd quarter, Holdings Channel reports. The fund owned 46,535 shares of the company’s stock after buying an additional 46,034 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Adicet Bio were worth $661,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cowen AND Company LLC boosted its holdings in Adicet Bio by 62.9% in the second quarter. Cowen AND Company LLC now owns 2,443,780 shares of the company’s stock worth $35,679,000 after acquiring an additional 943,725 shares in the last quarter. BlackRock Inc. boosted its holdings in Adicet Bio by 11.4% in the first quarter. BlackRock Inc. now owns 1,618,107 shares of the company’s stock worth $32,314,000 after acquiring an additional 165,655 shares in the last quarter. Polar Capital Holdings Plc boosted its holdings in Adicet Bio by 1.1% in the first quarter. Polar Capital Holdings Plc now owns 1,543,670 shares of the company’s stock worth $30,827,000 after acquiring an additional 16,397 shares in the last quarter. Candriam S.C.A. bought a new position in Adicet Bio in the second quarter worth approximately $18,740,000. Finally, DAFNA Capital Management LLC boosted its holdings in Adicet Bio by 30.7% in the second quarter. DAFNA Capital Management LLC now owns 935,766 shares of the company’s stock worth $13,662,000 after acquiring an additional 219,894 shares in the last quarter.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ACET. HC Wainwright raised their target price on Adicet Bio from $34.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 12th. StockNews.com began coverage on Adicet Bio in a report on Wednesday, October 12th. They set a “sell” rating on the stock. Finally, Wedbush lifted their price target on Adicet Bio to $30.00 in a report on Wednesday, November 16th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Adicet Bio presently has an average rating of “Moderate Buy” and a consensus price target of $27.71.
Adicet Bio Price Performance
NASDAQ:ACET opened at $8.84 on Monday. The business has a fifty day simple moving average of $12.52 and a two-hundred day simple moving average of $14.90. Adicet Bio, Inc. has a 1 year low of $7.42 and a 1 year high of $21.87. The company has a market capitalization of $378.80 million, a P/E ratio of -6.05 and a beta of 2.29.
Adicet Bio (NASDAQ:ACET – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.03. As a group, analysts anticipate that Adicet Bio, Inc. will post -1.54 earnings per share for the current year.
Adicet Bio Company Profile
Adicet Bio, Inc is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
- Get a free copy of the StockNews.com research report on Adicet Bio (ACET)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.